AHA 2023 CardioNerds Conference Scholars Late-Breaking Video Collection
Published: 16 November 2023
14m 58sPart 1 | Session 1 ORBITA-2: PCI for Stable Angina Rasha Al-Lamee, Nazli Okumus, Christopher Rajkumar
11m 47sPart 1 | Session 2 SELECT: Effects of Semaglutide on Heart Disease & Stroke in Obese Patients A Michael Lincoff , Ahmed Ghoneem
16m 5sPart 1 | Session 3 MINT: Myocardial Ischaemia & Transfusion Nazli Okumus, Jeffrey L Carson
11m 41sPart 1 | Session 4 KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension George L Bakris, Sukriti Banthiya
8m 35sPart 1 | Session 5 CordiO App: Speech Analysis to Detect Worsening HF in ADHF Patients Hanad Bashir, William T Abraham
14m 32sPart 1 | Session 6 AHA23: Presidential Advisory on Cardiovascular-Kidney-Metabolic Health Ramy Doss, Chiadi E Ndumele
10m 36sPart 1 | Session 7 AZALEA-TIMI 71: Abelcibab Vs Rivaroxaban in Patients with AF Naima Maqsood, Christian Ruff
9m 14sPart 1 | Session 8 An Extended Duration Short-Interfering RNA Targeting Lp(a) Maryam Barkhordarian, Steven E Nissen
11m 15sPart 1 | Session 9 ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin Naima Maqsood, Jeff Healey
In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.
These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
More from this programme
Radcliffe & Cardionerds @AHA23
About the episode
AHA 2023 - Investigator, Dr Mandeep Mehra (Brigham and Women's Hospital, US) is interviewed by Dr Christian Inchaustegui (Oregon Health & Science University, US), CardioNerds Ambassador, on the findings of the ARIES HM3 trial (NCT04069156).
ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two different antithrombotic regimens. One treatment group received a Vitamin K antagonist, whereas another group received a vitamin K antagonist with placebo.
The non-inferiority endpoint for this study will be met if the placebo arm is non-inferior to the aspirin arm in the composite of survival free of any non-surgical major hemocompatibility-related adverse event at one-year post-implant.
Results showed that excluding aspirin from an antithrombotic regime that includes a VKA in advanced heart failure patients with an LVAD was non-inferior to an aspirin-containing regimen, and was associated with decreased bleeding events without increased risk of thromboembolic events. There was also a 47% decrease in days spent in the hospital, and a 41% reduction in the cost of care for bleeding events. Researchers estimate that for each 100 patients implanted with the study LVAD, aspirin avoidance therapy prevented 14.5 major bleeding events in the first year.
Recorded on-site at AHA 2023, Philadelphia.
Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
Dr Mandeep R Mehra was born on December 3rd, 1967 in Delhi, India— the historic day Christiaan Barnard carried out the first human heart transplant.7 One of the country’s leading cardiologists in advanced heart failure and cardiac transplantation, he is a Professor of Medicine at Harvard Medical School and the Medical Director of the Brigham and Women’s Hospital (BWH) Heart and Vascular Center.5
Dr. Mehra says heart center cardiologists and surgeons practice a form of medicine that mirrors the vision of the future, which is cardiac care that is predictive, personalized, preemptive and participatory. His time at the University of Maryland Medical Center was marked by compassionate personalised care and a special emphasis on cardiac care for the whole person.3
An alumnus of the 1983 batch, Dr Mehra received his medical degree from Mahatma…
Christian is a Cardiology Fellow at Oregon Health & Science University in Portland, Oregon. He graduated from Cayetano Heredia University School of Medicine in Lima, Peru, and completed his Internal Medicine Residency and Chief Residency at Baylor College of Medicine, in Houston, Texas. His interests include hemocompatibility in mechanical circulatory support, critical care cardiology, advanced heart failure, and medical education. He enjoys hiking, biking, and jogging across the PNW with his wife and their Shiba-Chow pup, Laura.